HIF-1 as a target for drug development

By Amato J. Giaccia, B. Siim, Richard J. Johnson. Nature reviews. Drug discovery, 2003

620 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/d70b2020b690990792b57437300528872545e1cc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. D. Hanahan
2. A. Mantovani
3. M. C. Simon
4. N. Denko
5. G. Bergers
6. V. Nizet
7. Jessica A. Bertout
8. P. Allavena

In Molecular Biology

1. D. Hanahan
2. N. Denko
3. A. Sica
4. P. Allavena
5. G. Bergers
6. Jessica A. Bertout
7. M. C. Simon
8. A. Mantovani

In Physiology

1. H. El-Gabalawy
2. M. C. Simon
3. A. Sica
4. Richard J. Johnson
5. A. Mantovani
6. C. Hitchon
7. D. Hanahan

Citations in the corpus

• Radiation oncology: a century of achievements (2004, neutral): “fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3091,405">HIF1 ) transcription facto”
• Role of tumor-associated macrophages in tumor progression and invasion (2006, background): “Similarly to NF-κB, inhibition of HIF-1α is considered a promising therapeutic approach against cancer [48] and in fact some of its inhibitors (e.”
• Oxidation in rheumatoid arthritis (2004, background): “The central role of HIF-1α in mediating hypoxic responses has suggested new therapeutic opportunities, particularly in cancer and cardiovascular medicine [ 130 ,131].”
• Modes of resistance to anti-angiogenic therapy (2008, background): “The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
• The impact of O2 availability on human cancer (2008, background): “The role of HIFs in cancer On the basis of the analysis of human cancer biopsy samples and experimental animal models, it has become increasingly clear that HIFs have a crucial role in cancer progressio”
• Exploiting tumour hypoxia in cancer treatment (2004, background): “Targeting HIF-1 The characteristics, functions and possibilities for targeting HIF-1 in cancer therapy have been recently reviewe”
• Hypoxia, HIF1 and glucose metabolism in the solid tumour (2008, background): “HIF1 inhibitors with metabolic effects Investigators are also attempting to inhibit the HIF1 transcription factor in an effort to block the metabolic effects as well as other physiological pathways that are regulated by HIF1 in the solid tumour (such as angiogenesis”
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions (2023, background): “HIF-1α is an oxygen-unstable protein that becomes stable in response to hypoxia, iron chelators, and divalent cations.(81,82) In cell culture under hypoxic conditions, HIF-1α mRNA levels did not change, but HIF-1α protein levels increased.”
• HIF Transcription Factors, Inflammation, and Immunity (2014, background): “In this regard, HIF-1a inhibition could be a potential strategy for limiting exacerbated responses, such as arthritis (Giaccia et al., 2003).”
• Targeting hypoxia in cancer therapy (2011, background): “Multiple components of the HIF1 signalling pathway have been identified as candidate drug target”